Mountain Group Partners

United States
Firm Location:United States • Nashville, Tennessee
Investor Firms That Co-Invest with Mountain Group Partners
Mountain Group Partners Team
Photo of Joe Cook III, Managing Director at Mountain Group Partners
Joe Cook III
Mountain Group Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Nashville (TN)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A)
Photo of Joe Cook Jr, Managing Director at Mountain Group Partners
Joe Cook Jr
Mountain Group Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Nashville (TN)
Photo of Rob Readnour, Managing Director at Mountain Group Partners
Rob Readnour
Mountain Group Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Nashville (TN)
Photo of Steve Singleton, Managing Director at Mountain Group Partners
Steve Singleton
Mountain Group Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Nashville (TN)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in LegalTech (Series A), Investors in LegalTech (Seed), Investors in LegalTech (Series B)
Photo of Jack Slaughter, Vice President at Mountain Group Partners
Jack Slaughter
Mountain Group Partners·Vice President
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Nashville (TN)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A)
Photo of Byron Smith, Managing Director at Mountain Group Partners
Byron Smith
Mountain Group Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Nashville (TN)
Photo of Tyler Whitmore, Vice President at Mountain Group Partners
Tyler Whitmore
Mountain Group Partners·Vice President
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Nashville (TN)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A)